Этот перевод готовится. Пока мы временно показываем оригинальную версию на английском языке.
Бизнес · 28.10.20191 мин чтения
Watson Laboratories, Inc.; Proposal To Withdraw Approval of an Abbreviated New Drug Application for Oxycodone Hydrochloride and Ibuprofen Tablets; Opportunity for a Hearing
Локальный автоматический перевод · Язык оригинального источника
Краткое содержание
The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of an abbreviated new drug application (ANDA) for oxycodone hydrochloride and ibuprofen tablets and is announcing an opportunity for the holder of the ANDA to request a hearing on this proposal. The basis for the proposal is that the holder of the ANDA has repeatedly failed to submit the required data to support a finding of bioequivalence for this ANDA.
Язык оригинального источника: Federal Register — Food and Drug AdministrationОткрыть исходное сообщение →